European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Approval follows accelerated assessment, orphan designation by European Medicines Agency TOKYO, Oct. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") ... Biopharmaceuticals, Oncology, Regulatory Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news